Spero Therapeutics (SPRO) EBIT (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly EBIT came in at -$7.5 million in Q1 2026, up 48.83% YoY from -$5.1 million in Q1 2025, and down 125.76% on a QoQ basis from $29.3 million in Q4 2025.
Spero Therapeutics (SPRO) EBIT (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of EBIT data on file, last reported at -$7.5 million in Q1 2026.
- Quarterly EBIT rose 48.83% year-over-year to -$7.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.9 million (up 116.31% YoY) and the FY2025 annual result came in at $6.3 million, up 108.61% from the prior year.
- EBIT slipped to -$7.5 million in Q1 2026, from $29.3 million in the prior quarter.
- In the past five years, EBIT ranged from a high of $47.7 million in Q4 2023 to a low of -$30.2 million in Q1 2022.
- A 5-year average of -$6.0 million and a median of -$12.9 million in 2023 frame the typical range for EBIT.
- Annual changes were most pronounced in 2024 — EBIT tumbled 801.6% — and 2025, when it jumped 234.69%.
- Tracing SPRO's EBIT over 5 years: stood at $21.7 million in 2022, then soared by 119.55% to $47.7 million in 2023, then slumped by 145.59% to -$21.7 million in 2024, then jumped by 234.69% to $29.3 million in 2025, then plunged by 125.76% to -$7.5 million in 2026.
- The last three EBIT figures came in at -$7.5 million (Q1 2026), $29.3 million (Q4 2025), and -$7.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | -9.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.93 Mn |
| Mar 31, 2026 | -7.54 Mn |
| Dec 31, 2025 | 29.26 Mn |
| Sep 30, 2025 | -7.38 Mn |
| Jun 30, 2025 | -2.44 Mn |
| Mar 31, 2025 | -14.73 Mn |
| Dec 31, 2024 | -21.73 Mn |
| Sep 30, 2024 | -17.44 Mn |
| Jun 30, 2024 | -19.06 Mn |
| Mar 31, 2024 | -13.98 Mn |
| Dec 31, 2023 | 47.66 Mn |
| Sep 30, 2023 | -1.93 Mn |
| Jun 30, 2023 | -12.89 Mn |
| Mar 31, 2023 | -14.23 Mn |
| Dec 31, 2022 | 21.71 Mn |
| Sep 30, 2022 | -11.83 Mn |
| Jun 30, 2022 | -26.08 Mn |
| Mar 31, 2022 | -30.21 Mn |
| Dec 31, 2021 | -27.50 Mn |
| Sep 30, 2021 | -22.52 Mn |